“Must See” Abstracts at 2024 ASCO

One of the most significant gatherings of oncology professionals is almost upon us. As you plan your time at ASCO®, keep an eye out for these top research studies highlighted by Cleveland Clinic leadership.

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

Time	Title	Abstract/Poster #	Location
9:00 AM – 12:00 PM CDT, June 1	Study of ELU001, a C’Dot drug conjugate (CDC) targeting folate receptor α (FRα) overexpressing solid tumors	Abstract #TPS3173/ Poster #311b	Hall A
9:00 AM-12:00 PM CDT, June 1	Establishing a protocol to increase racial/ethnic minority enrollment on an active radiation oncology randomized clinical trial	Abstract #TPS1638/ Poster #509a	Hall A
3:12 PM CDT, June 1	Evaluation of a polygenic risk score as a predictor of early onset triple-negative breast cancer in Black women	Abstract #10501	S100a
4:00 PM CDT, June 1	Clinical behavior of breast cancer in young BRCA carriers and prognostic impact of the timing of genetic testing: Results from an international cohort study	Abstract #10503	S100a
4:36 PM CDT, June 2	Real-world outcomes of lisocabtagene maraleucel (liso-cel) in patients (pt) with Richter transformation (RT) from the Center for International Blood and Marrow Transplant Research (CIBMTR)	Abstract #7010	E450b
8:12 AM CDT, June 3	Patient-reported outcomes (PROs) from a randomized, phase 3 trial of enfortumab vedotin plus pembrolizumab (EV+P) versus platinum-based chemotherapy (PBC) in previously untreated locally advanced or metastatic urothelial cancer (la/mUC)	Abstract #4502	Hall 81
10:21 AM CDT, June 3	Tumor microbiome differences in early-onset versus average-onset pancreatic adenocarcinoma	Abstract #4016	E451
1:30-4:30 PM CDT, June 3	Effect of tumor burden on survival in patients with stage IV EGFR-mutant NSCLC receiving osimertinib monotherapy	Abstract #8611/ Poster #475	Hall A
1:30 PM CDT, June 3	Phase 1/2 study of the TGF-β-trap-enhanced oncolytic adenovirus, AdAPT-001, plus an immune checkpoint inhibitor for patients with immune refractory cancers	Abstract #2506	Hall D2
10:21 AM CDT, June 4	Assessing the prognostic value of transcriptomic data in multiple myeloma through machine learning methodologies	Abstract #7513	S102
Time
9:00 AM – 12:00 PM CDT, June 1
Title
Study of ELU001, a C’Dot drug conjugate (CDC) targeting folate receptor α (FRα) overexpressing solid tumors
Abstract/Poster #
Abstract #TPS3173/ Poster #311b
Location
Hall A
9:00 AM-12:00 PM CDT, June 1
Title
Establishing a protocol to increase racial/ethnic minority enrollment on an active radiation oncology randomized clinical trial
Abstract/Poster #
Abstract #TPS1638/ Poster #509a
Location
Hall A
3:12 PM CDT, June 1
Title
Evaluation of a polygenic risk score as a predictor of early onset triple-negative breast cancer in Black women
Abstract/Poster #
Abstract #10501
Location
S100a
4:00 PM CDT, June 1
Title
Clinical behavior of breast cancer in young BRCA carriers and prognostic impact of the timing of genetic testing: Results from an international cohort study
Abstract/Poster #
Abstract #10503
Location
S100a
4:36 PM CDT, June 2
Title
Real-world outcomes of lisocabtagene maraleucel (liso-cel) in patients (pt) with Richter transformation (RT) from the Center for International Blood and Marrow Transplant Research (CIBMTR)
Abstract/Poster #
Abstract #7010
Location
E450b
8:12 AM CDT, June 3
Title
Patient-reported outcomes (PROs) from a randomized, phase 3 trial of enfortumab vedotin plus pembrolizumab (EV+P) versus platinum-based chemotherapy (PBC) in previously untreated locally advanced or metastatic urothelial cancer (la/mUC)
Abstract/Poster #
Abstract #4502
Location
Hall 81
10:21 AM CDT, June 3
Title
Tumor microbiome differences in early-onset versus average-onset pancreatic adenocarcinoma
Abstract/Poster #
Abstract #4016
Location
E451
1:30-4:30 PM CDT, June 3
Title
Effect of tumor burden on survival in patients with stage IV EGFR-mutant NSCLC receiving osimertinib monotherapy
Abstract/Poster #
Abstract #8611/ Poster #475
Location
Hall A
1:30 PM CDT, June 3
Title
Phase 1/2 study of the TGF-β-trap-enhanced oncolytic adenovirus, AdAPT-001, plus an immune checkpoint inhibitor for patients with immune refractory cancers
Abstract/Poster #
Abstract #2506
Location
Hall D2
10:21 AM CDT, June 4
Title
Assessing the prognostic value of transcriptomic data in multiple myeloma through machine learning methodologies
Abstract/Poster #
Abstract #7513
Location
S102

“These abstracts to be presented at the 2024 ASCO Annual Meeting represent collaborative work led by Cleveland Clinic oncologists, spanning a range of important areas of research, including early phase clinical trials of novel drugs, methods to increases diversity in clinical trials, studies of predictive factors of relapse, survival and response to therapies, real-world and patient-reported outcomes research, as well as the tumor microbiome,” says James Stevenson, MD.

Find more details about ASCO abstracts.

“Must See” Abstracts at 2024 ASCO Annual Meeting

Related Articles

Study Finds No Connection Between OSMs and Increased Cancer Rates in IBD Patients

Offering Rehabilitation Care to Oncology Patients (Podcast)

Managing Hormone Dysfunction-Related Adverse Events of Immunotherapy for Breast Cancer Treatment

Cleveland Clinic Cancer Center and National Organization for Rare Disorders Partner to Accelerate Diagnosis and Treatment of Rare Cancers

Cleveland Clinic Lerner Research Institute to Host Head & Neck Cancer CME Symposium

Pathway Cross-Talk Suggests New Approach to Glioblastoma Treatment

Patient With Stage 4 Triple-Negative Breast Cancer in Remission 10 Years After Initial Diagnosis

Eye Toxicities More Prevalent Side Effect of Cancer Treatment Than Previously Understood